Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.

ABSTRACT:

Background

We retrospectively explored changes in immunological parameters in men with biochemically recurrent prostate cancer treated with either 5 or 25 mg of lenalidomide in a randomized phase 2 trial, and determined whether those changes correlated with disease progression.

Methods

Cytokine levels were compared for each patient at baseline and after 6 months of treatment with lenalidomide. Regression models for correlated data were used to assess associations of cytokine levels with lenalidomide treatment effect. Estimates were obtained using generalized estimating equations. Changes in circulating anti-prostate antibodies were evaluated using a high-throughput immunoblot technique.

Results

Treatment with lenalidomide was associated with global changes in immunore

SUBMITTER: Zabransky DJ 

PROVIDER: S-EPMC3248613 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature